SCHEMBL29330322

SCHEMBL29330322

Cc1[nH]c(=O)c(C(C)(C)C)cc1C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.35
▸ GAA P10253 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GRIN2D O15399 1/20 0.34
▸ GRIN3B O60391 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2A Q12879 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ GRIN2C Q14957 1/20 0.34
▸ GRIN3A Q8TCU5 1/20 0.34
▸ DAO P14920 1/20 0.34
▸ ALDH1A1 P00352 5/20 0.33
▸ PDE3B Q13370 5/20 0.33
▸ PDE3A Q14432 5/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CA2 P00918 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ TYR P14679 1/20 0.33
▸ GLRA3 O75311 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850530 0.84 KDM4E (0.47) KDM4EGAAHPGDHSD17B10GRIN2D
SCHEMBL12402395 0.73 ALDH1A1 (0.37) KDM4EGAAHPGDHSD17B10ALDH1A1
SCHEMBL29330288 0.71 ALDH1A1 (0.38) KDM4EGAAHPGDDAOALDH1A1
SCHEMBL21719469 0.70 ALDH1A1 (0.34) KDM4EALDH1A1SMN1; SMN2CA2POLB
SCHEMBL23686003 0.68 LMNA (0.38) KDM4EALDH1A1PDE3BPDE3ACA2
SCHEMBL22674257 0.68 HMBS (0.43) KDM4EGAAHPGDGRIN2DGRIN3B
SCHEMBL19779639 0.67 DAO (0.60) KDM4EGAAHPGDHSD17B10DAO
SCHEMBL20193913 0.67 DAO (0.60) KDM4EGAAHPGDHSD17B10DAO
SCHEMBL24061201 0.67 DAO (0.52) KDM4EHSD17B10DAOALDH1A1SMN1; SMN2
SCHEMBL837270 0.66 BRD4 (0.59) KDM4EHPGDHSD17B10GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043613-B2 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP KDM4E 3087/4885GAA 1897/4885HPGD 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback